Efficiency of using fibrinolysis inhibitor to reduce intraoperative blood loss in patients with disseminated ovarian cancer after 3 cycles of neoadjuvant chemotherapy
Objective. To analyze the efficiency of intraoperative injection of Ambene to reduce blood loss during surgical treatment in patients with disseminated ovarian cancer after neoadjuvant chemotherapy. Subjects and methods. The investigation enrolled 36 patients with morphologically verified disseminated ovarian cancer (Stages III-IV). The patients were divided into 2 groups: a) those who had received intravenous Ambene intraoperatively (a study group) and 2) those who had undergone cytoreductive surgery without using hemostatic agents (a comparison group). Results. The Ambene-treated patients were observed to have a much lower volume of intraoperative blood loss than those who had no hemostatic therapy, which amounted to 80±12 and 550±11 ml, respectively. Conclusion. The findings are suggestive of the efficiency of single intraoperative administration of Ambene in patients with disseminated ovarian cancer after neoadjuvant chemotherapy.